CurifyLabs, based in Helsinki, has successfully secured €6.7M to enhance the production of compounded medications, which address specific patient requirements. This funding round, led by Springvest with support from Business Finland, aims to expand their operations amidst a growing global market for these personal medicines. CurifyLabs has raised a total of €17.6M and operates internationally. Their focus lies on revolutionizing an outdated medication manufacturing process, particularly for groups requiring customized prescriptions, thus ensuring accuracy and minimizing risks for vulnerable patients like children.
The current approach to manufacturing compounded medications is outdated and poorly optimised - failing both pharmacies and the patients they serve. Even with highly trained pharmacists and modern equipment, the process remains unnecessarily labour-intensive, prone to human error, and inconsistent in quality.
The consequences are real: a 9-month-old baby with cancer, for example, cannot swallow standard tablets and requires a carefully customised formulation. It's time to work together and modernise how we deliver personalised medicines.
Collection
[
|
...
]